VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,429,128 | +2.1% | 793,036 | 0.0% | 16.12% | +23.5% |
| Q2 2023 | $39,604,218 | +52.5% | 793,036 | +14.4% | 13.06% | +22.1% |
| Q1 2023 | $25,975,102 | -21.8% | 693,039 | 0.0% | 10.70% | -26.0% |
| Q4 2022 | $33,231,220 | +78.4% | 693,039 | -10.7% | 14.45% | +112.3% |
| Q3 2022 | $18,625,000 | +2.9% | 776,039 | -6.7% | 6.81% | -25.4% |
| Q2 2022 | $18,108,000 | -32.5% | 832,166 | -25.1% | 9.12% | -28.2% |
| Q1 2022 | $26,842,000 | +1.5% | 1,111,485 | 0.0% | 12.70% | +14.9% |
| Q4 2021 | $26,442,000 | -25.8% | 1,111,485 | -20.9% | 11.06% | -12.3% |
| Q3 2021 | $35,656,000 | +12.7% | 1,405,421 | 0.0% | 12.60% | +1.1% |
| Q2 2021 | $31,636,000 | +14.0% | 1,405,421 | 0.0% | 12.47% | +40.0% |
| Q1 2021 | $27,757,000 | -53.0% | 1,405,421 | -36.8% | 8.90% | -54.3% |
| Q4 2020 | $59,064,000 | – | 2,222,970 | – | 19.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |